Health

Dr. Elad Yossefi and Dr. Tal Yossefi Introduce Tech-Enhanced Dental Services in Norwalk

Norwalk, CT / USA, June 16, 2025 (GLOBE NEWSWIRE) -- Norwalk, CT — Advanced Dental Center in Norwalk, Connecticut, led…

1 year ago

Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results

June 16, 2025 18:40 ET  | Source: Enzo Biochem, Inc. FARMINGDALE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem,…

1 year ago

Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…

1 year ago

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical…

1 year ago

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever…

1 year ago

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with…

1 year ago

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients with Duchenne has been re-assessed,…

1 year ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in…

1 year ago

Avricore Grants Options

June 14, 2025 01:05 ET  | Source: Avricore Health Inc. VANCOUVER, British Columbia, June 14, 2025 (GLOBE NEWSWIRE) -- AVRICORE…

1 year ago